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CONCISE COMMUNICATION
Placental transfer of anti-group B Streptococcus
immunoglobulin G antibody subclasses from
HIV-infected and uninfected women
to their uninfected infants
Kirsty Le Doarea,b,c, Stephen Taylord, Lauren Allend,
Andrew Gorringed, Paul T. Heathb, Beate Kampmanna,c,
Anneke C. Hesselinge and Christine E. Jonesa,b,f
Objectives: Placental antibody transfer is impaired in the context of HIV infection,
which may render HIV-exposed, uninfected infants vulnerable to group B Streptococ-
cus (GBS) disease. The GBS antibody response predominately consists of immunoglo-
bulin G2 (IgG2) antibody. Thus we determined whether concentration and placental
transfer of anti-GBS antibody subclasses was altered in HIV-infected compared with
HIV-uninfected mothers.
Design: A retrospective analysis of anti-GBS antibody subclasses in 38 HIV-infected
and 33 HIV-uninfected mothers and their uninfected infants.
Methods: Sera were analysed using a novel flow cytometric assay that quantified
binding of IgG1, IgG2, IgG3 and IgG4 to serotype (ST)Ia, STIII and STV GBS bacteria.
Results: IgG2 binding to GBS STIa and V was lower in HIV-infected women compared
with HIV-uninfected women. Moreover, IgG2 binding to GBS STIa was also lower in
HIV-exposed, uninfected infants compared with unexposed infants. However, there
were no statistically significant differences in the transplacental transfer ratio of IgG2 for
anyGBS serotype. The transplacental transfer of total IgGwas reduced for GBS STIII and
V and IgG1 subclass for STIII; placental transfer of all other subclasses was comparable
in HIV-affected and HIV-unaffected pregnancies.
Conclusion: Anti-GBS IgG2 placental transfer is not affected by HIV infection. This is
important for functional antibody against the capsular polysaccharide of GBS and
provides confidence that maternal GBS vaccination may result in functional activity in
HIV-infected and uninfected women.
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Opsonophagocytosis of group B Streptococcus (GBS) is
mediated predominately by the immunoglobulin G2
(IgG2) subclass [1], which is poorly transported across the
placenta compared with IgG1 [2,3]. This may reflect the
lower affinity of IgG2 for the FcRn receptors on
syncytiotrophoblasts of placental cells as compared with
the other subclasses of IgG [4,5]. Studies comparing
maternal and infant antibody concentrations demonstrate
that anti-GBS capsular antibody is transferred across the
placenta with a high degree of efficiency [6]. However,
the proportionally higher concentration of antibody in
infant compared with maternal serum at birth is thought
to be mainly due to excess foetal IgG1 [2]. It has been
demonstrated for GBS serotype (ST) Ia and STIII that not
only is total anti-GBS antibody concentration lower in
GBS-infected infants than in infants without infection
born to colonized mothers [7,8], but that IgG2 is also
lower in infants with GBS infection [9]. Recent studies
have shown that maternal and placental transfer of total
anti-GBS antibody is reduced in the context of maternal
HIV-infection [10,11]. This might explain the greater
reported incidence of early, and especially late onset, GBS
disease observed amongst HIV-exposed, uninfected
infants compared with unexposed infants [12]. A West
African study identified hypergammaglobulinaemia as a
risk factor for reduced placental transfer of IgG subclasses
and this might be a further contributing factor to the
observed excess of GBS morbidity amongst HIV-exposed
infants [13]. Thus, we compared total and subclass anti-
GBS antibody placental transfer in HIV-infected and
HIV-uninfected South African women.
Methods
Samples were collected frommothers and infants enrolled
in a cohort study investigating the influence of maternal
HIV and mycobacterial sensitization on infant immune
responses to Bacillus Calmette-Gue´rin (BCG) vaccina-
tion carried out between 2009 and 2011 [14]. The
demographic details, CD4þ cell count, viral load and
antiretroviral medication have been previously described
[14]. Informed consent was obtained from all mothers
participating in the study. The study was approved by the
Universities of Cape Town (382/2008) and Stellenbosch
(N08/10/278), South Africa, and the National Health
Service Research Ethics Committee, England (07/
H0720/178).
Paired sera from 38 HIV-infected and 33 HIV-uninfected
mothers and their uninfected infants were available to
analyse immunoglobulin subclasses. Deposition of total
IgG and IgG1, IgG2, IgG3 and IgG4 anti-GBS antibody
subclasses onto the surface of formaldehyde-fixed GBS
bacteria was measured using a flow cytometric assay
performed in 96-well microtitre plates as previously
described [10]. Mouse monoclonal antibodies: 4E3
antihuman IgG1 H&L, HP6014 antihuman IgG2 fd
gamma, HP6050 antihuman IgG3 hinge heavy chain and
mouse HP6025 antihuman IgG4 Fc (FITC) (Life
Technologies, Carlsbad, California, USA) (1 : 500) in
blocking buffer were added and samples incubated for 20
min at 48C. Assays were analysed using a Beckman
Coulter Cyan flow cytometer equipped with a Cytek 96-
well microtitre plate loader. A fluorescence index (FI) was
calculated for each sample, which involved the multipli-
cation of the percentage of bacteria in the horizontal gate
(%-gated), by the mean fluorescence of that population
(X-mean). The final result for each test was expressed as
the average FI of duplicate test samples minus the average
FI of the bacteria and conjugate-only control. A standard
unit (SU) measurement for each serum sample was then
calculated by comparing to the serum FI response
obtained with the positive control serum for each
serotype which was given an arbitrary value of 1000
(kind gift from Professor Carol Baker, Baylor College of
Medicine, Texas, USA) to give a result in SU/ml.
Statistical analyses were completed using STATA version
12 (StataCorp 2013, College Station, Texas, USA) and
GraphPad Prism version 6.0 (GraphPad Software Inc., La
Jolla, California, USA). The sample size was calculated to
demonstrate a 50% difference in IgG subclass concen-
trations between HIV-exposed and HIV-unexposed
infants with the predefined assumption that antibody
subclass concentrations would be lower in HIV-exposed
infants. Using an a error of 5%, 80% test power and a 95%
confidence interval, the sample size ranged from 10 to 30
in each group. Placental transfer was defined as the ratio of
infant-to-mother GBS IgG concentration at birth.
Missing data were excluded from analysis. We considered
P values less than 0.05 as statistically significant.
Results
The paired sera from 71 mother–infant dyads (38 HIV-
infected mothers and their uninfected infants and 33
HIV-uninfected mothers and their infants) at birth were
available for analysis of total IgG, IgG1 and IgG2 for all
serotypes. For serotypes ST1a and STV, sufficient sera was
available from 60 mother–infant pairs to analyse
subclasses IgG3 and IgG4. Sufficient sera were available
from 40 mother–infant pairs for analysis of IgG3 and
IgG4 for STIII.
Antibody subclass concentrations
Concentrations of anti-GBS IgG1 in mothers and infants
were higher than concentrations of IgG2 for all GBS
serotypes, independent of HIV status (Fig. 1).
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For STIa, HIV-uninfected women had significantly
higher geometric mean concentration (GMC) of subclass
IgG2 and IgG4 than HIV-infected women (IgG2 2.3
[95% confidence interval (CI) 1.6–3.3] vs. 5.9 [4.0–8.9]
SU/ml, P¼ 0.02; IgG4 1.8 [0.9–3.6] vs. 18.6 [6.0–57.8]
SU/ml, P¼ 0.03) but comparable concentrations of IgG1
and IgG3 (Fig. 1). In HIV-unexposed compared with
HIV-exposed, uninfected infants, there was a significantly
higher concentration of IgG2 (P¼ 0.03) and IgG4
(P¼ 0.03). In addition, we noted a trend towards higher
concentrations of anti-STIa IgG1 and lower concen-
tration of IgG3 but this did not reach statistical
significance (Fig. 1).
For STV, HIV-infected women had a trend towards
higher concentrations of IgG1 than HIV-uninfected
women (P¼ 0.049) and HIV-uninfected women had
significantly higher concentrations of IgG2 than HIV-
infected women (P¼ 0.047), although the concentration
of IgG2 was low in both groups. HIV-unexposed infants
had higher concentrations of anti-STV IgG3 antibody
compared with HIV-exposed infants (P¼ 0.039). There
was no statistical difference between HIV-exposed,
uninfected infants and HIV-unexposed infants for any
of the other IgG subclasses (Fig. 1).
There was no significant difference between anti-STIII
IgG subclasses in HIV-infected and HIV-uninfected
women and HIV-exposed, uninfected and HIV-
unexposed infants.
Placental transport of total group B
Streptococcus antibody
Total IgG transplacental antibody transfer ratio (TPR)
was reduced in HIV-infected compared with HIV-
uninfected women for GBS STIII [0.6 (0.3–1.1) vs. 1.3
(0.8–2.3) SU/ml, P¼ 0.04] and STV [1.2 (0.7–1.6) vs.
2.0 (1.1–3.0) SU/ml, P¼ 0.04] but not for STIa. (Table
1). There was no association between CD4þ cell count or
viral load and TPR.
Placental transport of subclasses group B
Streptococcus antibody
TPR of IgG1 was decreased to HIV-exposed infants
compared with HIV-unexposed infants [0.4 (0.1–1.4) vs.
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Fig. 1. Anti-group B Streptococcus subclass distribution in
HIV-infected and HIV-uninfected mothers and their unin-
fected infants at birth. HIV–, HIV uninfected; HIVþ, HIV
infected; IgG, immunoglobulin G; ST, serotype; SU/ml, stan-
dard units per millilitre. Horizontal bars compare groups,
P<0.05.
Table 1. Geometric mean concentration (GMC) transplacental transfer ratios of total and subclass IgG1, IgG2, IgG3 and IgG4 against GBS STIa,
III and V in HIV-infected and HIV-uninfected mothers to their infants [95% confidence interval (CI)].
STIa STIII STV
HIVþ HIV– P HIVþ HIV– P HIVþ HIV– P
Total 1.1 (0.8–1.6) 1.0 (0.6–1.6) 0.75 0.6 (0.3–1.1) 1.3 (0.8–2.3) 0.04 1.2 (0.7–1.6) 2.0 (1.1–3.0) 0.04
IgG1 1.0 (0.7–1.5) 1.4 (1.0–2.0) 0.44 0.4 (0.1–1.4) 1.3 (0.7–2.5) 0.04 1.0 (0.7–1.4) 1.4 (0.9–2.1) 0.14
IgG2 0.9 (0.5–1.5) 0.7 (0.5–1.2) 0.43 1.1 (0.4–3.2) 0.8 (0.4–1.4) 0.38 0.7 (0.5–1.1) 0.8 (0.6–1.1) 0.59
IgG3 0.3 (0–9) 1.0 (0.3–3.3) 0.5 0.9 (0.6–1.4) 1.3 (0.8–2.1) 0.23
IgG4 0.5 (0.2–1.1) 1.6 (0–4) 0.08 1.2 (0.5–2.9) 0.6 (0.3–1.4) 0.31
GBS, group B Streptococcus; HIV–, HIV-uninfected; HIVþ, HIV infected; IgG, immunoglobulin G; ST, serotype.
1.3 (0.7–2.5) SU/ml; P¼ 0.04] for STIII but not for STIa
or STV (Table 1). The TPR for IgG2 was unaffected by
maternal HIV infection status for any serotype. There
were no statistical differences between antibody TPR for
any other subclass or any other serotype of GBS between
groups.
Discussion
Our findings demonstrate that whilst total transplacental
transfer ratios are reduced in HIV-infected mothers for
GBS STIII and V, the proportion of individual subclasses
transferred from mother to infant is unaffected by
maternal HIV infection, with the exception of IgG1 to
GBS STIII. Importantly, there was no difference in the
placental transfer of IgG2 that bounds to any of the
GBS serotypes.
HIV-exposed, uninfected infants may be at increased risk
of GBS infection, in particular late onset disease [10,12]
The observation that there is no difference in the
proportion of IgG subclass placental transfer (except for
IgG1 for STIII) may mean that HIV-exposed, uninfected
infants are at increased risk of disease as a result of their
mother’s reduced total antibodies that bind to GBS
bacteria, rather than a selective deficit in IgG2 transfer. It
may alternatively be due to impaired B cell function in the
context of HIV infection that results from poor function
of T helper cellular response and function of antibody in
the context of HIV-infection [15].
The fact that IgG2 surface deposition was lower in HIV-
exposed infants to STIa and in women to STV in HIV-
infected women may indicate reduced antibody function
due toHIV-infection. In this studywewere unable to assess
the opsonophagocytic ability of the antibodywhich would
provide additional information on the functional ability of
antibody to protect from GBS infection. In studies of
pneumococcal vaccination, opsonophagocytosis was
impaired in HIV-infected compared with HIV-uninfected
individuals and the same may be true of GBS [16].
The serotypes we have selected in this study represent
77% of colonizing strains in South African pregnant
women (STIII, 33%; STIa, 39%; STV, 12% [17]). They
also represent 86.1% of early onset GBS disease and 100%
of late onset disease (STIII 57.7% of early onset, 84.4% of
late onset disease; STIa 22.6%/ 13.9%; STV 5.8%/1.9%
[18]). Thus, the serotype-specific antibody observed
corresponds to the predominant colonizing and disease-
causing serotypes in South Africa.
Although patients with HIV disease develop high levels of
total IgG in serum soon after infection [19], the IgG1
subclass is preferentially increased, whereas levels of total
IgG2may be normal or decreased [20].We confirmed the
relatively similar concentration of IgG2 antibody that
binds to GBS STIII in the sera of HIV-infected and HIV-
uninfected women. IgG2 responses to the bacterial
capsular polysaccharide in humans may be driven in part
by IFN-y production [21], whichmay be impaired during
HIV-infection [22]. However, HIV-infected patients in
our cohort showed no selective deficit in IgG2
production. The differences in subclass distribution by
GBS serotype may be as a result of different reactivity of
the different serotypes in our assay. However, comparison
with the larger study demonstrated good correlation
between total antibody concentrations for all serotypes
tested [10].
Maternal HIV infection has been associated with reduced
placental transfer of antibodies against several common
viral and bacterial antigens [23,24]. Additionally, the
finding that HIV-exposed, uninfected infants are more
likely to have sub-protective antibody levels to vaccine
preventable diseases means that these infants are likely to
be more prone to these diseases in early childhood. Our
finding that the placental transfer of IgG2 subclass,
important for the opsonization and killing of GBS, was
not impaired indicates potential for a maternal vaccine to
boost both maternal and infant immunity in areas of high
HIV-prevalence.
Our sample size was limited and we are not able to draw
conclusions on other possible effects of HIV-infection on
placental transfer. Additionally, we cannot comment on
the colonizing serotypes of the mothers. However, the
fact that the antibody against the major GBS serotypes was
detected in all women suggests prior colonization with
GBS. Finally, we cannot comment on protective levels of
antibody in this population, as there were no cases of GBS
disease in our cohort.
In summary, the decreased concentration of serum IgG that
bounds to the surface of GBS in HIV-infected women and
their infants comparedwith non-HIV-infected dyads is not
due to a selective defect in the generation of GBS-specific
IgG2 antibody. Future efforts should address enhancing
protective antibody concentrations through maternal
vaccination against GBS during pregnancy to optimize
IgG2 concentration in the neonate.
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